Cargando…

The class II histone deacetylases as therapeutic targets for Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by specific motor impairments. The neuropathological hallmarks of PD include progressive degeneration of midbrain dopaminergic neurons, and loss of their axonal projections to the striatum. Additionally, there is prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazzocchi, Martina, Collins, Louise M, Sullivan, Aideen M., O'Keeffe, Gerard W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373248/ https://www.ncbi.nlm.nih.gov/pubmed/32714601 http://dx.doi.org/10.1042/NS20200001

Ejemplares similares

Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling
por: Mazzocchi, Martina, et al.
Publicado: (2019)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease
por: O'Keeffe, Gerard W., et al.
Publicado: (2017)

Editorial: The Role of Stem Cells, Epigenetics and MicroRNAs in Parkinson's Disease
por: Hegarty, Shane V., et al.
Publicado: (2020)

Class-Specific Histone Deacetylase Inhibitors Promote 11-Beta Hydroxysteroid Dehydrogenase Type 2 Expression in JEG-3 Cells
por: Togher, Katie L., et al.
Publicado: (2017)

The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease
por: Goulding, Susan R., et al.
Publicado: (2020)

Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2017)

Neurotrophic factor therapy for Parkinson's disease: past, present and future
por: Sullivan, Aideen M., et al.
Publicado: (2016)

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease
por: Goulding, Susan R., et al.
Publicado: (2021)

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
por: Wang, Guan, et al.
Publicado: (2012)

Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2014)

Protocol for evaluation of neurotrophic strategies in Parkinson’s disease-related dopaminergic and sympathetic neurons in vitro
por: Hegarty, Shane V., et al.
Publicado: (2016)

Diet quality, sleep and quality of life in Parkinson’s disease: a cross-sectional study
por: Dunk, Danielle, et al.
Publicado: (2022)

Association of distinct type 1 bone morphogenetic protein receptors with different molecular pathways and survival outcomes in neuroblastoma
por: Alshangiti, Amnah M., et al.
Publicado: (2020)

Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against α-Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells
por: McCarthy, Erin, et al.
Publicado: (2022)

Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease
por: Hegarty, Shane V., et al.
Publicado: (2018)

Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease
por: Costello, Daniel J, et al.
Publicado: (2012)

Subcellular Localization of Class I Histone Deacetylases in the Developing Xenopus tectum
por: Guo, Xia, et al.
Publicado: (2016)

Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson’s disease
por: Collins, Louise M, et al.
Publicado: (2014)

Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
por: Li, Yan, et al.
Publicado: (2022)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

Medicinal chemistry advances in targeting class I histone deacetylases
por: Abdallah, Diaaeldin I., et al.
Publicado: (2023)

Histone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic Injury
por: Aune, Sverre E., et al.
Publicado: (2015)

NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson’s Disease
por: Anantha, Jayanth, et al.
Publicado: (2021)

Targeting Histone Deacetylases: A Novel Approach in Parkinson's Disease
por: Sharma, Sorabh, et al.
Publicado: (2015)

Histone deacetylases and their role in motor neuron degeneration
por: Lazo-Gómez, Rafael, et al.
Publicado: (2013)

Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia
por: Bai, Guang, et al.
Publicado: (2010)

Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy
por: Kee, Hae Jin, et al.
Publicado: (2011)

Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
por: Torres, Haydee M., et al.
Publicado: (2021)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
por: Badie, Amandine, et al.
Publicado: (2022)

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics
por: Schator, Daniel, et al.
Publicado: (2021)

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
por: Korfei, Martina, et al.
Publicado: (2022)

Expression of Class I and Class II a/b Histone Deacetylase is Dysregulated in Hypertensive Animal Models
por: Kee, Hae Jin, et al.
Publicado: (2017)

The class II histone deacetylase HDAC4 regulates cognitive, metabolic and endocrine functions through its expression in osteoblasts
por: Makinistoglu, Munevver Parla, et al.
Publicado: (2014)

Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
por: Lemos, Miguel, et al.
Publicado: (2020)

STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5
por: Anantha, Jayanth, et al.
Publicado: (2020)

Expression of class II histone deacetylases in two mouse models of temporal lobe epilepsy
por: Jagirdar, Rohan, et al.
Publicado: (2015)

A short guide to histone deacetylases including recent progress on class II enzymes
por: Park, Suk-Youl, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m6qjifq5v7q4jg6o1bctfdngtj